EU Crunch Time For 15 New Drugs At Final CHMP Meeting Of 2021
Oral Explanation Meetings Possible For Four Marketing Applications
Executive Summary
Drugs for COVID-19, Alzheimer’s disease and heavy menstrual bleeding due to uterine fibroids are among the latest products that are this week being considered for marketing approval by the European Medicine Agency’s human drugs evaluation committee, the CHMP.
You may also be interested in...
Idorsia’s Insomnia Drug Daridorexant Among 14 Hopefuls For EU Verdict
The European Medicines Agency will likely decide this week whether to recommend for pan-EU approval new treatments for insomnia, uveal melanoma, migraine and advanced prostate cancer.
Novel Sickle Cell Treatment Among 13 New Drugs On Track For EU Approval
A first-of-its-kind drug for uterine fibroids and a new monoclonal antibody treatment for COVID-19 are among several new drugs recommended for pan-EU approval this month.
Intercept Withdraws EU NASH Drug Filing But May Retry
New data that is being collected to support a US resubmission for Intercept’s obeticholic acid might also be used to support a resubmission to the European Medicines Agency.